The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
Our scientists found that toxicological data for most PFAS are incomplete or unavailable, leaving significant uncertainty about consumer safety
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The approval is supported by data from three pivotal clinical trials
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
The accelerated review covers WCK 5222 for multiple critical infections
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Subscribe To Our Newsletter & Stay Updated
